EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience
Dae Won Kim1, Jennifer Byer, Nishi Kothari
1Department of Gastrointestinal Oncology, Moffit Cancer Center, Tampa, FL, USA.
Background:
Although squamous cell anal carcinomas are relatively rare, their incidence has been increasing steadily. Because of the limited data, treatment of metastatic disease is a major therapeutic challenge. In this study, we report the safety and efficacy of epidermal growth factor receptor (EGFR) inhibitors in patients with advanced squamous cell anal carcinomas.
Method:
A retrospective analysis was conducted using the Moffitt Cancer Tumor Registry from January 2009 to January 2014. Eligible patients had diagnosis of advanced squamous cell anal carcinomas and received an EGFR inhibitor as part of their treatment.
Result:
A total of 13 patients were identified for analysis. All of them received concurrent chemoradiation as initial treatment and subsequently had recurrence. Five patients received single agent cetuximab or panitumumab, and the others received cetuximab or panitumumab with irinotecan or FOLFIRI. The objective response rate was 30.8% including 1 complete response, and the disease control rate was 46.2%. With a median follow-up of 9.6 months, the median progression-free survival and median overall survival were 4.4 months and 11.4 months, respectively.
Conclusion:
Our analysis suggests that EGFR inhibitors have potential efficacy and are reasonably well tolerated in patients with squamous cell anal carcinomas. These findings warrant further evaluation in a large prospective trial.
Insights
Epidermal growth factor receptor (EGFR) inhibitors show promise for treating advanced squamous cell anal carcinomas. This retrospective study found these targeted therapies to be safe and effective in patients with recurrent disease.
Area of Science:
- Oncology
- Medical Research
Background:
- Squamous cell anal carcinoma incidence is rising, posing a therapeutic challenge for metastatic cases.
- Limited data exists for treating advanced squamous cell anal carcinomas.
- Epidermal growth factor receptor (EGFR) inhibitors are being investigated for advanced squamous cell anal carcinomas.
Purpose of the Study:
- To evaluate the safety and efficacy of EGFR inhibitors in patients with advanced squamous cell anal carcinomas.
- To assess response rates and survival outcomes for EGFR inhibitor therapy in this patient population.
Main Methods:
- Retrospective analysis of 13 patients with advanced squamous cell anal carcinomas treated with EGFR inhibitors.
- Data collected from January 2009 to January 2014.
- Patients received EGFR inhibitors (cetuximab or panitumumab) alone or in combination with chemotherapy (irinotecan or FOLFIRI) after initial treatment and recurrence.
Main Results:
- Objective response rate was 30.8% (1 complete response).
- Disease control rate was 46.2%.
- Median progression-free survival was 4.4 months and median overall survival was 11.4 months.
Conclusions:
- EGFR inhibitors demonstrate potential efficacy in treating advanced squamous cell anal carcinomas.
- These targeted therapies appear to be well-tolerated in this patient group.
- Further validation in prospective trials is warranted.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle